17027-50-8 Usage
Uses
Used in Pharmaceutical Industry:
3-[(4S)-2,5-dioxoimidazolidin-4-yl]propionic acid is used as a key intermediate in the synthetic preparation of glutathione analogs, which are important for their potential therapeutic applications in various diseases and conditions. These analogs can help modulate the immune system, protect cells from oxidative stress, and support detoxification processes.
Used in Biochemistry Research:
In the field of biochemistry, 3-[(4S)-2,5-dioxoimidazolidin-4-yl]propionic acid is used as a building block for the synthesis of peptide nucleic acids (PNAs). PNAs are a type of nucleic acid analog that can form stable duplexes with complementary DNA or RNA strands, making them valuable tools for molecular biology research and potential therapeutic agents.
Used in Organic Synthesis:
3-[(4S)-2,5-dioxoimidazolidin-4-yl]propionic acid is also used as a versatile synthetic building block in the preparation of various organic compounds, including phosphonooligopeptides from heterocyclic imines. These compounds can have potential applications in medicinal chemistry, materials science, and other fields that require the development of novel organic molecules with specific properties and functions.
Check Digit Verification of cas no
The CAS Registry Mumber 17027-50-8 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 1,7,0,2 and 7 respectively; the second part has 2 digits, 5 and 0 respectively.
Calculate Digit Verification of CAS Registry Number 17027-50:
(7*1)+(6*7)+(5*0)+(4*2)+(3*7)+(2*5)+(1*0)=88
88 % 10 = 8
So 17027-50-8 is a valid CAS Registry Number.
17027-50-8Relevant academic research and scientific papers
Maddileti,Nangia, Ashwini
, p. 5252 - 5265 (2015)
Carglumic acid (CGA) is used for the treatment of hyperammonaemia. The aim of this study was to investigate novel crystalline forms of CGA which can offer improved physicochemical properties and also to understand the stability relationships between such forms. We report two novel polymorphs I and II and a degradation derivative of the drug hydantoin-5-propionic acid (5-HPA). Crystallization conditions have been optimized to obtain each polymorph in reproducible crystallization batches. 5-HPA was obtained serendipitously upon crystallization of CGA in acidic medium (2-butanone : propionic acid). The X-ray crystal structures of CGA Form-I and Form-II and 5-HPA are sustained by carboxylic acid catemer and dimer, carboxamide catemer and dimer and an acid-amide heterosynthon. The two polymorphs are monotropically related. Thermodynamic stability, phase transformation, and Hirshfeld surface maps complement the structural analysis. Both forms are stable for two months under accelerated ICH conditions of 40 °C and 75% RH. Dynamic vapor sorption (DVS) showed that Form-I is more stable under moisture conditions than Form-II. Slurry crystallization, mechanical grinding and thermal measurements confirm the thermodynamic nature of CGA Form-I.
